TELA Bio Balance Sheet Health

Financial Health criteria checks 2/6

TELA Bio has a total shareholder equity of $-6.3M and total debt of $41.0M, which brings its debt-to-equity ratio to -653.2%. Its total assets and total liabilities are $53.0M and $59.3M respectively.

Key information

-653.2%

Debt to equity ratio

US$40.97m

Debt

Interest coverage ration/a
CashUS$17.30m
Equity-US$6.27m
Total liabilitiesUS$59.29m
Total assetsUS$53.02m

Recent financial health updates

Recent updates

Even With A 27% Surge, Cautious Investors Are Not Rewarding TELA Bio, Inc.'s (NASDAQ:TELA) Performance Completely

Nov 09
Even With A 27% Surge, Cautious Investors Are Not Rewarding TELA Bio, Inc.'s (NASDAQ:TELA) Performance Completely

Not Many Are Piling Into TELA Bio, Inc. (NASDAQ:TELA) Stock Yet As It Plummets 33%

Aug 19
Not Many Are Piling Into TELA Bio, Inc. (NASDAQ:TELA) Stock Yet As It Plummets 33%

Does TELA Bio (NASDAQ:TELA) Have A Healthy Balance Sheet?

Jul 03
Does TELA Bio (NASDAQ:TELA) Have A Healthy Balance Sheet?

Shareholders May Be More Conservative With TELA Bio, Inc.'s (NASDAQ:TELA) CEO Compensation For Now

May 29
Shareholders May Be More Conservative With TELA Bio, Inc.'s (NASDAQ:TELA) CEO Compensation For Now

TELA Bio, Inc. (NASDAQ:TELA) Soars 31% But It's A Story Of Risk Vs Reward

May 23
TELA Bio, Inc. (NASDAQ:TELA) Soars 31% But It's A Story Of Risk Vs Reward

Earnings Update: TELA Bio, Inc. (NASDAQ:TELA) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Mar 24
Earnings Update: TELA Bio, Inc. (NASDAQ:TELA) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Many Still Looking Away From TELA Bio, Inc. (NASDAQ:TELA)

Mar 08
Many Still Looking Away From TELA Bio, Inc. (NASDAQ:TELA)

TELA Bio (NASDAQ:TELA) Has Debt But No Earnings; Should You Worry?

Oct 07
TELA Bio (NASDAQ:TELA) Has Debt But No Earnings; Should You Worry?

Getting In Cheap On TELA Bio, Inc. (NASDAQ:TELA) Might Be Difficult

Jul 31
Getting In Cheap On TELA Bio, Inc. (NASDAQ:TELA) Might Be Difficult

TELA Bio: Tailwinds In Hernia Repair Market And Promising Clinical Data To Drive Accelerating Adoption

Oct 02

Tela Bio prices $32M common stock offering

Aug 16

Is TELA Bio (NASDAQ:TELA) Using Debt Sensibly?

May 12
Is TELA Bio (NASDAQ:TELA) Using Debt Sensibly?

TELA Bio - Follow Up With Management

Jan 14

Our First Look At TELA Bio

Nov 04

TELA Bio Plugging Away

Oct 25

TELA Bio (TELA) Investor Presentation - Slideshow

May 26

Financial Position Analysis

Short Term Liabilities: TELA has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: TELA has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: TELA has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: TELA's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TELA has sufficient cash runway for 5 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: TELA is forecast to have sufficient cash runway for 4 months based on free cash flow estimates, but has since raised additional capital.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/22 17:14
End of Day Share Price 2025/02/21 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

TELA Bio, Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kyle RoseCanaccord Genuity
William PlovanicCanaccord Genuity
Caitlin CroninCanaccord Genuity